长风药业（02652）今日在港交所挂牌上市，股价表现亮眼，盘中大涨218.64%，引发市场广泛关注。该公司专注于呼吸系统疾病治疗领域，此次上市反映了投资者对其业务前景的看好。
根据公告，长风药业的发售价定为每股14.75港元。上市首日开盘价报47港元，较发售价大幅上涨218.64%。截至上午交易时段，成交额已达2.71亿港元。值得注意的是，公司此前公开发售部分获得6697.8倍超额认购，反映了投资者对该股的热烈追捧。国际配售部分也录得12.74倍认购。每手500股，不计手续费，账面收益高达16,125港元。
长风药业主要专注于吸入技术及吸入药物的研发、生产及商业化，产品组合覆盖广泛患者群体和治疗领域。公司首个获批产品CF017（吸入用布地奈德混悬液）用于治疗支气管哮喘，是中国销量最高的吸入药物类别。据悉，CF017在2024年占中国布地奈德吸入药物市场约16%的份额。公司在临床开发、生产、监管事务及商业化方面的能力备受认可，已从国家药监局和美国FDA获得六项产品批准。长风药业此次上市融资净额约5.25亿港元，将主要用于产品研发、生产设施扩张及升级等方面，以支持公司未来发展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.